DÄ internationalArchive42/2021Consider Vaccine Dose Adjustment

Correspondence

Consider Vaccine Dose Adjustment

Dtsch Arztebl Int 2021; 118: 722. DOI: 10.3238/arztebl.m2021.0291

Seydel, J

LNSLNS

The authors report pronounced vaccine reactions after administration of the first dose of the AstraZeneca vaccine and put a dose adjustment up for discussion (1).

In the pivotal study that led to approval of the AstraZeneca vaccine, significantly less adverse reactions after the first dose of vaccine were noted in patients receiving a lower initial dose (2.2 × 1010 viral particles) in comparison to the standard dose (3.5–6.5 × 1010 viral particles) (2). In the age group of 18–55 years, moderate to strong vaccine reactions were associated with low-dose and standard dose administrations and occurred with frequencies of 32% and 53%, respectively. In addition, in this age group and in participants with intervals of at least eight weeks between doses, efficacy of 90.0% was seen in those who received a low dose as prime and then the standard dose, compared to 65.6% in trial participants who received the standard dose at both occasions (3).

Administration of a lower initial dose of AstraZeneca vaccine showed good efficacy with a lower rate of adverse reactions and has the potential to improve acceptance of the vaccination. Furthermore, because of the reduced vaccine use, more people could be vaccinated.

DOI: 10.3238/arztebl.m2021.0291

Dr. med. Johannes Seydel

Hannover, Germany seydel12@mailbox.org

1.
Ziemann M, Görg S: Inability to work after corona vaccination in medical staff. Dtsch Arztebl Int 2021; 118: 298–9 VOLLTEXT
2.
Ramasamy M, Minassian AM, Ewer KJ, et al.: Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine administered in a prime-boost regimen in older adults (COV002): a phase 2/3 single blind, randomised controlled trial. Lancet 2020; 396: 1979–93 CrossRef
3.
Voysey M, Costa Clemens SA, Madhi SA, et al.: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111 CrossRef
1.Ziemann M, Görg S: Inability to work after corona vaccination in medical staff. Dtsch Arztebl Int 2021; 118: 298–9 VOLLTEXT
2.Ramasamy M, Minassian AM, Ewer KJ, et al.: Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine administered in a prime-boost regimen in older adults (COV002): a phase 2/3 single blind, randomised controlled trial. Lancet 2020; 396: 1979–93 CrossRef
3.Voysey M, Costa Clemens SA, Madhi SA, et al.: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111 CrossRef

Info

Specialities